ATE481497T1 - Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a - Google Patents
Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3aInfo
- Publication number
- ATE481497T1 ATE481497T1 AT02739923T AT02739923T ATE481497T1 AT E481497 T1 ATE481497 T1 AT E481497T1 AT 02739923 T AT02739923 T AT 02739923T AT 02739923 T AT02739923 T AT 02739923T AT E481497 T1 ATE481497 T1 AT E481497T1
- Authority
- AT
- Austria
- Prior art keywords
- pde3a
- isoforms
- pde3
- methods
- phosphodiesterases
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30927101P | 2001-08-01 | 2001-08-01 | |
PCT/US2002/019319 WO2003012030A2 (en) | 2001-08-01 | 2002-06-19 | Isoform-selective inhibitors and activators of pde3 cyclic |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE481497T1 true ATE481497T1 (de) | 2010-10-15 |
Family
ID=23197473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02739923T ATE481497T1 (de) | 2001-08-01 | 2002-06-19 | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a |
Country Status (7)
Country | Link |
---|---|
US (3) | US20030158133A1 (de) |
EP (1) | EP1430140B1 (de) |
JP (1) | JP2004536614A (de) |
AT (1) | ATE481497T1 (de) |
AU (1) | AU2002312543A1 (de) |
DE (1) | DE60237696D1 (de) |
WO (1) | WO2003012030A2 (de) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003012030A2 (en) | 2001-08-01 | 2003-02-13 | University Of Utah, Technology Transfer Office | Isoform-selective inhibitors and activators of pde3 cyclic |
US9513288B2 (en) * | 2001-08-01 | 2016-12-06 | The United States Of America As Represented By The Department Of Veterans Affairs | Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases |
AU2003280241A1 (en) * | 2002-11-01 | 2004-05-25 | Mcmaster University | Multicomponent protein microarrays |
WO2004071377A2 (en) * | 2003-02-17 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with phosphodiesterase 3a (pde3a) |
AU2004275903B2 (en) | 2003-09-29 | 2012-04-12 | Topigen Pharmaceutique Inc. | Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
EP1579862A1 (de) | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern |
JP2005326165A (ja) * | 2004-05-12 | 2005-11-24 | Hitachi High-Technologies Corp | タンパク質相互作用解析のための抗タグ抗体チップ |
CA2628570A1 (en) | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
EP3210605A1 (de) | 2005-11-14 | 2017-08-30 | Boehringer Ingelheim Vetmedica GmbH | Verwendung von pde-iii-hemmern zur behandlung asymptomatischem (okkultem) herzversagen |
WO2007134451A1 (en) | 2006-05-19 | 2007-11-29 | Topigen Pharmaceuticals Inc. | Oligonucleotides affecting expression of phosphodiesterases |
EP1920785A1 (de) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat |
JP5775299B2 (ja) * | 2007-04-10 | 2015-09-09 | アンセルム(アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) | 血管障害治療のためのmrp4阻害剤 |
PT2370070E (pt) | 2008-11-25 | 2013-11-18 | Boehringer Ingelheim Vetmed | Utilização de pimobendano para o tratamento da cardiomiopatia hipertrófica felina |
EP2401365B1 (de) * | 2009-02-24 | 2016-04-27 | The Scripps Research Institute | Reengineering einer mrna-primärstruktur für erhöhte proteinproduktion |
AU2010226604A1 (en) | 2009-03-19 | 2011-10-13 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120029054A1 (en) | 2009-03-19 | 2012-02-02 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA) |
EP2408916A2 (de) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der genexpression von ctgf (connective tissue growth factor) unter verwendung von sina (short interfering nucleic acid) |
US20120004282A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp, | RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2411516A1 (de) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | Rna-interferenz-vermittelte hemmung der genexpression von ask1 (apoptose-signalregulierende kinase 1) unter verwendung von sina (short interfering nucleic acid) |
WO2010111490A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012521763A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたシグナル伝達性転写因子1(STAT1)遺伝子発現のRNA干渉媒介性阻害 |
WO2012018754A2 (en) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
EP2609198B8 (de) | 2010-08-24 | 2018-03-28 | Sirna Therapeutics, Inc. | Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer |
US9233997B2 (en) | 2010-08-26 | 2016-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA) |
CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2707251C2 (ru) | 2011-10-03 | 2019-11-25 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
ES2924478T3 (es) | 2012-03-15 | 2022-10-07 | Boehringer Ingelheim Vetmedica Gmbh | Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
EP2833892A4 (de) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | Modifizierte polynukleotide zur herstellung von in der onkologie nützlichen proteinen und peptiden |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CN113181110A (zh) | 2013-07-19 | 2021-07-30 | 勃林格殷格翰动物保健有限公司 | 含有防腐的醚化的环糊精衍生物的液体水性药物组合物 |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015082389A1 (en) | 2013-12-04 | 2015-06-11 | Boehringer Ingelheim Vetmedica Gmbh | Improved pharmaceutical compositions of pimobendan |
US9994830B2 (en) | 2014-07-15 | 2018-06-12 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods for modulating cyclic nucleotide-mediated signaling in cardiac myocytes and compositions |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
WO2023069987A1 (en) | 2021-10-20 | 2023-04-27 | University Of Rochester | Rejuvenation treatment of age-related white matter loss cross reference to related application |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) * | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) * | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) * | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) * | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) * | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4215051A (en) * | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
US4366241A (en) * | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4883750A (en) * | 1984-12-13 | 1989-11-28 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4987071A (en) * | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
DE68908054T2 (de) | 1988-01-21 | 1994-03-10 | Genentech Inc | Verstärkung und nachweis von nukleinsäuresequenzen. |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
US5624824A (en) * | 1989-03-24 | 1997-04-29 | Yale University | Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
US5168053A (en) * | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
US5614396A (en) * | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
US5603872A (en) * | 1991-02-14 | 1997-02-18 | Baxter International Inc. | Method of binding recognizing substances to liposomes |
ATE132367T1 (de) * | 1991-02-14 | 1996-01-15 | Baxter Int | Bindung substratspezifischer affinitätssubstanzen an liposomen |
US5358866A (en) * | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5596079A (en) * | 1991-12-16 | 1997-01-21 | Smith; James R. | Mimetics of senescent cell derived inhibitors of DNA synthesis |
CA2127461A1 (en) * | 1992-01-13 | 1993-07-22 | Michael D. Been | Enzymatic rna molecules |
CA2064683A1 (en) * | 1992-03-26 | 1993-09-27 | Krishna Mohan Rao Kallury | Formation of thermostable enzymes with extra-ordinary heat tolerance by immobilization on phospholipid matrices |
US5279721A (en) * | 1993-04-22 | 1994-01-18 | Peter Schmid | Apparatus and method for an automated electrophoresis system |
AU1313095A (en) * | 1993-12-23 | 1995-07-10 | Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbb plays a role |
US5986076A (en) * | 1994-05-11 | 1999-11-16 | Trustees Of Boston University | Photocleavable agents and conjugates for the detection and isolation of biomolecules |
US6071394A (en) * | 1996-09-06 | 2000-06-06 | Nanogen, Inc. | Channel-less separation of bioparticles on a bioelectronic chip by dielectrophoresis |
US5585069A (en) * | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
US6068829A (en) * | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
US6031071A (en) * | 1996-01-24 | 2000-02-29 | Biophage, Inc. | Methods of generating novel peptides |
US5798246A (en) * | 1996-03-25 | 1998-08-25 | Incyte Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
CA2238283C (en) * | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
US5948627A (en) * | 1997-05-30 | 1999-09-07 | One Lambda | Immunobead flow cytometric detection of anti-HLA panel-reactive antibody |
AU8280798A (en) * | 1997-07-03 | 1999-01-25 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
AU9509798A (en) * | 1997-09-25 | 1999-04-12 | University Of Florida | Antisense oligonucleotide compositions targeted to angiotensi n converting enzy me mrna and methods of use |
US6210892B1 (en) * | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
US6100037A (en) * | 1999-01-07 | 2000-08-08 | Incyte Pharmaceuticals, Inc. | Human cyclic nucleotide PDEs |
US6146876A (en) * | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
US6380161B1 (en) * | 1999-06-21 | 2002-04-30 | Inkine Pharmaceutical Company, Inc. | Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions |
US6310047B1 (en) * | 1999-08-24 | 2001-10-30 | Virginia Commonwealth University | High affinity DNA binding compounds as adjuvants in antisense technology |
AU3270301A (en) * | 1999-11-13 | 2001-05-30 | Icos Corporation | Combined pde3 and pde4 inhibitor therapy for the treatment of obesity |
WO2001044449A1 (en) | 1999-12-14 | 2001-06-21 | University Of Utah Research Foundation | TWO NOVEL cAMP-SPECIFIC PHOSPHODIESTERASE (PDE4B) ISOFORMS AND RELATED TECHNOLOGY |
US6303374B1 (en) * | 2000-01-18 | 2001-10-16 | Isis Pharmaceuticals Inc. | Antisense modulation of caspase 3 expression |
DK1145717T3 (da) * | 2000-04-13 | 2004-08-02 | Pfizer Prod Inc | Synergistisk virkning af glyburid og milrinon |
US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
WO2003012030A2 (en) * | 2001-08-01 | 2003-02-13 | University Of Utah, Technology Transfer Office | Isoform-selective inhibitors and activators of pde3 cyclic |
WO2009002462A1 (en) * | 2007-06-22 | 2008-12-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pre-mirna loop-modulated target regulation |
-
2002
- 2002-06-19 WO PCT/US2002/019319 patent/WO2003012030A2/en active Application Filing
- 2002-06-19 AT AT02739923T patent/ATE481497T1/de not_active IP Right Cessation
- 2002-06-19 US US10/175,161 patent/US20030158133A1/en not_active Abandoned
- 2002-06-19 DE DE60237696T patent/DE60237696D1/de not_active Expired - Lifetime
- 2002-06-19 AU AU2002312543A patent/AU2002312543A1/en not_active Abandoned
- 2002-06-19 JP JP2003517208A patent/JP2004536614A/ja active Pending
- 2002-06-19 EP EP02739923A patent/EP1430140B1/de not_active Expired - Lifetime
-
2007
- 2007-01-18 US US11/654,858 patent/US8722866B2/en not_active Expired - Fee Related
-
2014
- 2014-03-27 US US14/227,426 patent/US9513289B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20140350047A1 (en) | 2014-11-27 |
US9513289B2 (en) | 2016-12-06 |
US20030158133A1 (en) | 2003-08-21 |
JP2004536614A (ja) | 2004-12-09 |
US8722866B2 (en) | 2014-05-13 |
US20100267046A1 (en) | 2010-10-21 |
AU2002312543A1 (en) | 2003-02-17 |
EP1430140B1 (de) | 2010-09-15 |
WO2003012030A3 (en) | 2004-04-08 |
WO2003012030A2 (en) | 2003-02-13 |
EP1430140A4 (de) | 2005-01-26 |
EP1430140A2 (de) | 2004-06-23 |
DE60237696D1 (de) | 2010-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE481497T1 (de) | Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a | |
ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
MY133159A (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
CY2607B2 (en) | Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists | |
DK2014678T3 (da) | KDR-peptider og vacciner indeholdende disse | |
ES2083595T3 (es) | Derivados de indol que inhiben la biosintesis de leucotrienos. | |
BR9811956B1 (pt) | naftiridinonas e composição farmacêutica compreendendo as mesmas. | |
ATE468336T1 (de) | Azolylaminoazine als proteinkinasehemmer | |
EA200100337A1 (ru) | Стабильные жидкие составы ботулинического токсина | |
DE69830404D1 (de) | P38-inhibitoren | |
SI1583541T1 (sl) | Spojine in postopki za povečanje nevrogeneze | |
ATE416772T1 (de) | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin | |
DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
DE69412486T2 (de) | Rekombinante viren und ihre verwendung bei der gentherapie | |
DE69809726T2 (de) | Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene | |
PT1149092E (pt) | 4- e 5-alciniloxindois e 4- e 5-alceniloxindois | |
MXPA03011505A (es) | Composiciones para cabello. | |
NO992282L (no) | Benzonaftyridiner som bronkialterapentika | |
NO20031159D0 (no) | Melkesyrebakterier som er i stand til å redusere et individs tendens til åutvikle allergiske reaksjoner | |
ES2171417T3 (es) | Uso de aislados de bacillus thuringiensis para controlar plagas de la familia aphididae. | |
SE8902532L (sv) | Bestaemning av plasmaproteiner | |
AU6469401A (en) | Pharmaceutically active compounds and methods of use | |
DK1147212T3 (da) | T-hjælpecelle-epitoper | |
DE69426121T2 (de) | Gen grb3-3, variante und ihre verwendungen | |
TR200101493T2 (tr) | Eletriptan hidrobromid monohidrat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |